Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

@article{Kyle2003CriteriaFT,
  title={Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group},
  author={Robert A. Kyle and J. Anthony Child and Kenneth C. Anderson and Bart Barlogie and Régis Bataille and William I. Bensinger and Joan Blad{\'e} and Mario Boccadoro and William S. Dalton and Meletios- Athanasios Dimopoulos and Benjamin Djulbegovic and Mark T. Drayson and Brian G. M. Durie and Thiery Facon and Rafael Fonseca and G{\"o}sta Gahrton and Philip R. Greipp and Jean Luc Harousseau and David P. Harrington and Mohamad A. Hussein and Douglas Edgar Joshua and Heinz Ludwig and Gareth J. Morgan and Martin M. Oken and Ray L. Powles and Paul G. Richardson and David G. Roodman and Jesús F. San Miguel and Kazuyuki Shimizu and Chaim Shustik and Bhawna Sirohi and Pieter Sonneveld and Guido Tricot and Ingemar Turesson and Brian Van Ness and David H Vesole and Donna M. Weber and Johan Westin and Keith Wheatley},
  journal={British Journal of Haematology},
  year={2003},
  volume={121}
}
Summary. The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy… Expand
Diagnostic evaluation of monoclonal gammopathy of undetermined significance
TLDR
In a substantial proportion of patients with MGUS, a bone marrow biopsy can be safely omitted from the diagnostic work-up, and clear data is provided that address this issue and provide support to the IMWG recommendations. Expand
Monoclonal gammopathies of renal significance.
TLDR
The main clinical and pathological features of monoclonal gammopathy of renal significance are summarized, highlighting the most appropriate diagnostic approach and current therapeutic options. Expand
Monoclonal gammopathy with renal significance
TLDR
The expert opinion is that the presence of monoclonal gammapathy is not a contraindication to kidney transplantation and treatment of renal disease should not differ from other patients with similar conditions not related to monoconal protein. Expand
Investigation of monoclonal gammopathy of undetermined significance: a single-centre study.
TLDR
This work investigates the frequency and features of monoclonal gammopathies and the malignant transformation of MGUS and focuses on the importance of regular clinical and laboratory control examinations. Expand
Evolving diagnostic criteria for multiple myeloma.
  • S. Rajkumar
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2015
TLDR
The current diagnosis and risk-stratification of SMM is reviewed, and it is possible to identify a subset of patients with SMM who have a risk of progression to MM of 25% per year (high-risk SMM). Expand
Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression
TLDR
Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end‐organ damage. Expand
Clinical and Population-based Studies in Multiple Myeloma and Monoclonal Gammopathy – Focus on Infections
TLDR
The treatment with intermediate-dose melphalan (Mel 100) and stem cell support in multiple myeloma patients relapsing after high dosemelphalan and autologous transplantation (ASCT) is concluded that Mel 100 is a viable therapeutic option in relapsed patients and the best efficacy was seen in patients with longlasting response after ASCT. Expand
Myeloma and MGUS
TLDR
Myeloma is generally a disease of elderly individuals and presents with variable problems including anaemia, bone pain, fractures, spinal cord compression, renal failure, hypercalcaemia, recurrent infections and hyperviscosity, and treatment combines anti-myeloma chemotherapy and supportive therapy. Expand
New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies.
TLDR
This review summarizes the existing literature in the pathobiology of multiple myeloma, and the pathological properties of the M-proteins, focusing on the mechanisms of the renal manifestations related to these abnormal proteins, especially glomerular injury. Expand
Discovering the Meaning of Monoclonal Gammopathy of Undetermined Significance: Current Knowledge, Future Challenges
TLDR
The goal of many recent studies aims at evaluating individual patients and their overall risk of progression, the detection of early signs of progression and the development of timely treatment strategies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
TLDR
New criteria for response and progression have been developed as a result of discussions between representatives of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and representatives ofThe Myelomas Working Committee of the Autologousblood and marrow transplant Registry (ABMTR) and the International Bone Marrowtransplant Registry (IBMTR). Expand
Monoclonal gammopathy of undetermined significance.
TLDR
In a series of 241 Mayo Clinic patients with a serum M-protein but no evidence of multiple myeloma, macroglobulinemia, primary amyloidosis, lymphoma, or related disorders, followed up for 20 to 35 years (median, 22 years), the condition of 19% remained stable, and one percent had an increase in the serumM-protein to 3.0 g/dL or more but did not require chemotherapy. Expand
Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.
TLDR
The identification of a particular subset of MGUS patients (MC < = or 1.5 g/dL, BMPC < 5%, no reduction in polyclonal Ig and no detectable light chain proteinuria) at very low-risk of evolution, who can be considered as having benign monoclonal gammopathies are described. Expand
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
TLDR
The number of residual polyclonal PCs was the most powerful single parameter for the discrimination between MGUS and MM patients at diagnosis, even when only stage I MM cases were considered. Expand
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.
  • R. Kyle
  • Medicine
  • The American journal of medicine
  • 1978
TLDR
Retrospective analysis of age, sex, presence of organomegaly, hemoglobin level, size and type of serum monoclonal protein peak, Presence of small amounts monoconal light chain in the urine, serum albumin level, levels of uninvolved immunoglobulins, IgG subclass and level of plasma cells in the bone marrow did not show how to distinguish initially between stable benign disease and progressive disease. Expand
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
TLDR
The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year, and the initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. Expand
"Benign" monoclonal gammopathy--after 20 to 35 years of follow-up.
  • R. Kyle
  • Medicine
  • Mayo Clinic proceedings
  • 1993
TLDR
In patients with an apparently benign monoclonal gammopathy, follow-up must be continued indefinitely because multiple myeloma, amyloidosis, macroglobulinemia, or related disorders occur in approximately a fourth of them. Expand
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
  • C. Cesana, C. Klersy, +7 authors E. Morra
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Careful evaluation of marrow plasmacytosis, urinary paraprotein, background immunoglobulins, ESR, and paraprotein isotype might help identify at presentation patients with benign monoclonal gammopathies requiring stricter monitoring. Expand
Blood clonal B‐cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation
TLDR
Cox's regression analysis showed that the presence of CBE was the most powerful predictor of progression to a malignant disease. Expand
The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases.
TLDR
The findings and the data in the literature suggest that MGUS could be considered a preneoplastic condition; since no clinical and laboratory features are able to identify in advance the patients at high risk of disease progression, each patient must be followed up indefinitely. Expand
...
1
2
3
4
...